Related Experiment Video

Updated: Aug 30, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

In vitro downregulation of growth factors by insulin-like growth factor binding protein-3 in cervical cancer

Rajesh S Mathur1, Subbi P Mathur

  • 1Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC 29425, USA. mathurs@musc.edu

Gynecologic Oncology
|November 6, 2003
PubMed
Abstract

Insights

Insulin-like growth factor binding protein 3 (IGF-BP3) reduces cervical cancer cell growth by downregulating epidermal growth factor receptor (EGF-R). Folic acid increases IGF-BP3, inhibiting cancer proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cervical cancer is linked to folate deficiency.
  • Epidermal growth factor receptor (EGF-R) and insulin-like growth factors (IGFs) play roles in cancer progression.
  • Insulin-like growth factor binding protein 3 (IGF-BP3) is a potential tumor suppressor.

Purpose of the Study:

  • To investigate the effect of IGF-BP3 on EGF-R, IGF-II, and vascular endothelial cell growth factor (VEGF) in cervical cancer cell lines.
  • To determine if folic acid supplementation can increase IGF-BP3 production and inhibit cervical cancer cell proliferation.

Main Methods:

  • Cervical cancer cell lines (HeLa, ME-180, HT-3) were treated with IGF-BP3.
  • Cellular levels of EGF-R, IGF-II, VEGF, and IGF-BP3 were measured using immunofluorescence assays.
  • The impact of folic acid and VEGF on IGF-BP3 levels was assessed.

Main Results:

  • IGF-BP3 treatment significantly reduced EGF-R, IGF-II, and VEGF levels in all tested cell lines.
  • Folic acid treatment increased cellular IGF-BP3 levels.
  • Vascular endothelial cell growth factor (VEGF) depleted cellular IGF-BP3.

Conclusions:

  • IGF-BP3 effectively downregulates key growth factors (EGF-R, IGF-II, VEGF) in cervical cancer cells.
  • Folic acid supplementation enhances IGF-BP3 production, suggesting a mechanism for inhibiting cervical cancer cell growth.
  • These findings highlight a potential therapeutic role for folic acid in managing cervical cancer.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...